Media and briefings

Latest posts

Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director
Prescient Therapeutics: Current Developments in Cancer Treatment
Prescient Therapeutics PTX-100 shows promising results in Phase 1b study
Prescient Therapeutics to present PTX-100 results at T-Cell Lymphoma Forum in California
Prescient Therapeutics to present PTX-100 results at 5th World Congress of Cutaneous Lymphomas
Prescient Therapeutics on cusp of value creation, says Pitt Street Research
Prescient Therapeutics (ASX: PTX) advances PTX-100 to pivotal Phase 2 study
Prescient Therapeutics secures speculative buy recommendation from Bioshares

Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director

Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has appointed accomplished medical professional Dr ...
Read More
/ Media, News, Proactive Investors

Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director

Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has appointed accomplished medical professional Dr ...
Read More
/ Media, News, Proactive Investors

Prescient Therapeutics: Current Developments in Cancer Treatment

Prescient Therapeutics, an ASX-listed company, is engaged in the development of drugs targeting various forms of cancer, with a specific ...
Read More
/ Media, News, Sub11

Prescient Therapeutics PTX-100 shows promising results in Phase 1b study

Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson in the Proactive studio ahead ...
Read More
/ Article, Media, News, Proactive Investors

Prescient Therapeutics to present PTX-100 results at T-Cell Lymphoma Forum in California

Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has been invited to present PTX-100 Phase 1b results at the 15th Annual T-Cell ...
Read More
/ Article, News, Proactive Investors

STAY UP TO DATE

Register your details to receive company updates from Prescient Therapeutics

Stay Updated

WEBCAST AND MEDIA

Prescient Therapeutics: Cell Therapies presentations from ISCT - 8th June 2023

Prescient Therapeutics: PTX-100 targeted cell therapy briefing - 2nd March 2023

Prescient Therapeutics CellPryme-A Briefing - 27 September 2022

Prescient Therapeutics (ASX:PTX) Investor Webcast - 10 June 2022

Prescient Therapeutics (ASX:PTX) Investor Webcast - 3 March 2022

Prescient Therapeutics (ASX:PTX) Investor Webcast - 19 October 2021

Prescient Therapeutics & Peter MacCallum Collaboration Update

Prescient Therapeutics with Special Guest Professor Miles Prince

Steven Yatomi Clarke on Stocks Down Under

ARTICLES

July 4, 2024
Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director
May 31, 2024
Prescient Therapeutics: Current Developments in Cancer Treatment
May 21, 2024
Prescient Therapeutics PTX-100 shows promising results in Phase 1b study
May 20, 2024
Prescient Therapeutics to present PTX-100 results at T-Cell Lymphoma Forum in California
April 8, 2024
Prescient Therapeutics to present PTX-100 results at 5th World Congress of Cutaneous Lymphomas
March 7, 2024
Prescient Therapeutics on cusp of value creation, says Pitt Street Research
January 10, 2024
Prescient Therapeutics (ASX: PTX) advances PTX-100 to pivotal Phase 2 study
January 9, 2024
Prescient Therapeutics secures speculative buy recommendation from Bioshares
December 19, 2023
Prescient to advance PTX-100 to phase II for refractory T-cell lymphomas

Follow us and stay connected

Prescient Therapeutics CEO interview from Pitt Street Research on Vimeo.